[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurocognitive-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurocognitive-dysfunction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,74,116,151,184,221,245,270,296],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100412215","hyperbaric-oxygen-therapy-for-post-covid-19-syndrome-100412215",false,"NCT04647656","Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome","Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome: a Prospective, Randomized, Double Blind Study.","HBOTpCOVID","Inclusion Criteria:\n\n1. Age above 18 years\n2. Reported post COVID-19 cognitive deterioration that effect quality of life and persist at least 3 months after confirmed infection.\n3. Subject willing and able to read, understand and sign an informed consent\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. History of traumatic brain injury (TBI) or any other non COVID brain pathology\n3. Active malignancy\n4. Substance use at baseline\n5. Severe or unstable physical disorders or major cognitive deficits at baseline\n6. HBOT for any reason prior to study enrolment\n7. Chest pathology incompatible with pressure changes (including moderate to severe asthma)\n8. Ear or Sinus pathology incompatible with pressure changes\n9. An inability to perform an awake brain MRI\n10. Active smoking","ALL","18 Years",{"count":20,"type":21},91,"ESTIMATED","INTERVENTIONAL",[24],"NA","Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome",[27,28],"Covid19","Neurocognitive Dysfunction","RECRUITING","2026-04-16",{"date":32,"type":33},"2026-04-21","ACTUAL",{"date":35,"type":33},"2023-06-01",{"date":37,"type":21},"2027-12-31",{"name":39,"class":40},"Assaf-Harofeh Medical Center","OTHER_GOV",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100624367","neurocognitive-deficit-after-paediatric-transplantation-understanding-the-role-of-environment-and-physical-function-100624367","NCT07408713","Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function","The NATURE Study (Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function)","NATURE","Inclusion Criteria:\n\n1. Recipient of allogeneic HSCT in the study period\n2. HSCT at the pediatric ward\n3. Age \\\u003C18 years at referral to HSCT\n4. Signed informed consent\n\nExclusion Criteria:\n\n1\\) Inability of legal guardian to speak and understand Danish","0 Years",{"count":52,"type":21},100,"OBSERVATIONAL","Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving treatment for children with relapsed or resistant leukemia and other life-threatening hematological and hereditary disorders. In Denmark, around 25 children undergo allogeneic HSCT every year, of these approximately 85-90% survive into adulthood.\n\nThe goal of this observational study is to learn about neurocognitive outcomes in children undergoing (HSCT) and to understand which clinical, physical, and environmental factors may affect neurocognitive development during the first year after transplant. The main questions it aims to answer are:\n\nHow does neurocognitive function change from before HSCT to one year after transplantation in pediatric patients?\n\nWhich clinical, physical, and environmental factors are linked to better or worse neurocognitive outcomes?\n\nParticipants will:\n\nComplete neurocognitive tests before HSCT and at 1-year follow-up, covering intelligence, memory, attention, executive function, processing speed, and motor skills.\n\nUndergo physical tests before HSCT, at hospital discharge, at 6-months follow-up, and at 1-year follow-up, including muscle strength, mobility, endurance, balance, and cardiopulmonary fitness (only at 1-year follow-up).\n\nWear activity trackers to measure physical activity and sedentary time during hospitalization at 6 months and 1-year post-HSCT.\n\nComplete questionnaires about sleep, pain, quality of life, fatigue, family background, and exposure to outdoor and green spaces.\n\nHave medical records reviewed for treatment-related side effects, immune recovery, inflammation, and pain management.\n\nThis study will help understand how neurocognitive function develops after HSCT in children and which factors (clinical, physical, or environmental) may support better recovery and well-being.",[56,57,58,59,60,28,61,62],"HSCT","Pediatric Cancer","Pediatric Patients","Late Effect","Toxicity","Physical Function","Physical Capacity","NOT_YET_RECRUITING","2026-02-18",{"date":66,"type":33},"2026-02-20",{"date":68,"type":21},"2026-02-15",{"date":70,"type":21},"2031-12-31",{"name":72,"class":73},"Rigshospitalet, Denmark","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":98,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":115},"100547838","remotely-supervised-tdcs-for-complex-attention-in-mtbi-cognetric-100547838","NCT06413173","Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)","Remotely Supervised tDCS Combined With Cognitive Training to Improve Complex Attention in Active Duty Service Members and Veterans With Mild TBI (Cognetric)","COGNETRIC","Inclusion Criteria:\n\n1. Active-Duty Service Members.\n2. Ages 18 to 60.\n3. All genders.\n4. All racial and ethnic groups.\n5. History of mild TBI (as defined by the DOD\u002FVA criteria used in conjunction with the OSU TBI-ID) sustained at least 3 months and no more than 10 years prior to enrollment.\n6. Self-reported attention and\u002For concentration difficulties.\n7. At least one cognitive symptom reported on the Neurobehavioral Symptom Inventory (NSI) cognitive subscale.\n\nExclusion Criteria:\n\n1. Presence of a medical, psychiatric, physical or non-physical disease, disorder, condition, injury, disability or pre-existent history such that study participation, in the opinion of the PI: (a) may pose a significant risk to the participant; (b) raises the possibility that the participant is unlikely to successfully complete all of the requirements of the study according to the study protocol; or (c) might adversely impact the integrity of the data or the validity of the study results. Specific conditions include (but are not limited to) a history of: brain tumor, epilepsy, cerebral vascular accident (CVA), Schizophrenia, Bipolar Disorder, and Mania.\n2. History of prior treatment with ECT or neuromodulation in the last 12 months.\n3. Current, diagnosed substance dependence.\n4. Newly prescribed medication within the previous 3 weeks.\n5. Diagnosis of intellectual disability or pervasive developmental disorder (i.e., premorbid IQ less than or equal to 70).\n6. Any medical condition or treatment other than mild TBI (e.g., stroke, tumor, HIV, moderate-severe TBI), with significant neurological disorder or insults that, based on the Principal Investigator's judgment, would impact risk.\n7. Psychosis or mania within 30 days of enrollment, as determined by the PI, based on a psychiatric history and examination and\u002For a review of available medical records\n8. Contraindications for tDCS (e.g., metallic cranial plates\u002Fscrews or implanted device, eczema or skin lesions on scalp)\n9. A positive pregnancy report.","60 Years",{"count":84,"type":21},160,[24],"The proposed study will evaluate a new approach to cognitive rehabilitation of mTBI using a brain stimulation technique called \"Remotely Supervised Transcranial Direct Current Stimulation combined with Cognitive Training\" (RS-tDCS+) which has shown promise for improving complex attention in both healthy and clinical populations. RS-tDCS+ is a home-based, low-risk, non-invasive technique that is designed to boost cognitive training by enhancing learning and the brain's ability to reorganize connections. This study will evaluate RS-tDCS+ for improving complex attention in Active Duty Service Members (ADSM) and Veterans with a history of mTBI. Different tests of complex attention and symptom questionnaires will be used to determine the effects of real versus sham (placebo) RS-tDCS+. Second, the investigators will investigate electrical and connectivity changes in the brain associated with RS-tDCS+ using electroencephalogram (EEG) and magnetic resonance imaging (MRI). Third, the investigators will investigate the lasting effects of any observed changes by evaluating participants at 1 and 6 weeks post-treatment. Lastly, the investigators will explore the impact of individual differences (e.g., PTSD, depression, sleep quality, time since injury, baseline impairment, age, sex, ADSM versus Veteran) on treatment outcome.",[88,89,90,91,92,28,93,94,95,96,97],"Brain Concussion","Brain Trauma","Attention Concentration Difficulty","Brain Injuries","Brain Injuries, Traumatic","Attention Impaired","Memory Impairment","Mild Traumatic Brain Injury","Mild Cognitive Impairment","Post Concussive Symptoms",[99,100,101,102,103,104],"Military Health","Brain Stimulation","Cognitive Training","Cognitive Rehabilitation","Telehealth","Neuromodulation","2025-11-07",{"date":107,"type":33},"2025-11-12",{"date":109,"type":33},"2024-07-25",{"date":111,"type":21},"2028-09-30",{"name":113,"class":114},"United States Naval Medical Center, San Diego","FED",2,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":127,"conditions":128,"keywords":137,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":41},"100458152","passive-sensor-identification-of-digital-biomarkers-to-assess-effects-of-orally-administered-nicotinamide-riboside-100458152","NCT05245903","Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside","Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia","Emerald-NRAD","Inclusion Criteria:\n\n* Ability of the participant and\u002For his\u002Fher legally authorized representative to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information.\n* Ability to speak and read fluently in English\n* 18-89 years old (inclusive)\n* Normal or corrected to normal hearing and vision\n* Meet clinical diagnostic criteria for MCI or Mild AD, according to the criteria outlined above\n* Study partner available for duration of trial participation\n* At least one copy of the APOE ε4 allele\n* An aggregate risk score \\> 4 according to the risk analysis method developed by Sabbagh et al. (2017)\n* For individuals who are taking niacin (or a vitamin supplement with niacin) of \\>200mg, the completion of a two-week wash-out period\n\nExclusion Criteria:\n\n* Current serious or unstable medical or neurological condition that could affect cognitive functioning, as determined by study clinician\n* Clinically unstable mood or anxiety disorder within 6 months prior to screening, as determined by study clinician\n* Lifetime history of psychotic disorder (i.e. Schizophrenia, Schizoaffective Disorder), as determined by study clinician\n* Diagnosis of a mitochondrial disorder\n* Any MRI safety contraindications\n* History of drug hypersensitivity or intolerance to NR\n* Transient ischemic attack or stroke within 1 year prior to screening\n* History of alcohol or substance abuse within prior year, as determined by study clinician and urine toxicology screen\n* History of head injury rated as moderate or worse, per DSM-5 criteria\n* History of seizure within prior 10 years\n* Current use of medication with known adverse effects on cognition (benzodiazepines, barbiturates, opiate analgesics, first generation antipsychotic medication, anticholinergics, sedating antihistamines, tricyclic anti-depressants)\n* Change in dose of any psychiatric medications within 4 weeks of screening visit\n* Prior use of L-DOPA, any anti-Parkinsonian medication, or prior treatment with anti-amyloid immunotherapy\n* Current use of putative mitochondrial enhancers or antioxidants (e.g. carnitine, creatine, Co-Q10, N-acetyl cysteine, pramipexole)\n* Initiation of treatment or change in dosing of acetylcholinesterase inhibitors (AChEIs) and memantine within 4 weeks of screening\n* Prior use of prescription narcotics 4 weeks before screening\n* Female subjects who are pregnant or breastfeeding\n* The current use of niacin (or a vitamin supplement with niacin) \\>200mg within the last two weeks prior to study visit","89 Years",{"count":126,"type":21},40,"This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.",[129,130,131,132,96,133,134,28,135,136],"Alzheimer Disease","Dementia Alzheimers","Dementia","Cognitive Impairment","Neurodegenerative Diseases","Neurocognitive Disorders","Cognitive Dysfunction","Mental Disorder",[138,139,140,96,141],"Passive sensing","Digital phenotyping","Alzheimer's Dementia","Digital biomarker","2025-11-04",{"date":144,"type":33},"2025-11-06",{"date":146,"type":33},"2022-05-31",{"date":148,"type":21},"2026-05-31",{"name":150,"class":73},"Mclean Hospital",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100467475","phase-2-ca-mg-butyrate-in-gwi-100467475","NCT05367245","Ca-Mg Butyrate in GWI","Microbiome Targeted Oral Butyrate Therapy in Gulf War Multisymptom Illness","Butyrate","Inclusion Criteria:\n\n* Gulf war era veteran deployed 40 and 70 years old, in good health by medical history prior to 1990 meeting GWI case definition of CDC and Kansas criteria and\n* currently have no exclusionary diagnoses (self- reported) that could reasonably explain the symptoms of their fatiguing illness. The severity of illness is moderate to severe, scoring less than 30 of 100 on the physical domain of VSF36 .\n\nExclusion Criteria:\n\n* Untreated schizophrenia,\n* Untreated bipolar disorder,\n* Untreated delusional disorders,\n* Untreated dementias of any type and\n* active alcoholism or drug abuse.\n* Medical conditions excluded include (i) organ failure, (ii) defined rheumatologic inflammatory disorders, and (iii) transplant.\n* Use of Butyrate in any form in the 3 months prior to study drug, medications that would impact gut motility, diarrhea, chronic pain, and immune function e.g., steroids, (Last 3 months)\n* immunosuppressive drugs or biologic response modifiers within 3 months of study entry will be used as exclusion criteria.\n* Pregnancy, or planned pregnancy in the next 6 months,\n* Body mass index more than 35\n* Specific diets that may have enhanced or enriched fiber or butyrogenic formulations (FODMAP)\n* Medications that could potentially impact immune function in the past one month will be excluded (e.g., steroids, antibiotics, immunosuppressives;\n* Medications containing supplement calcium or magnesium butyrate should not be taken for at least 3 months before study entry.\n* Nutraceuticals that are formulated to impact gut microbiome or immune health) and use of drugs that affect GI motility and use of any antibiotic in the last 2 months.\n* Known allergy to butyrate supplements or their derivatives such as sodium salts or hydroxy derivatives of butyrate and\u002For inactive ingredients of active and placebo soft gelatin will also be excluded.\n* Current evidence of celiac disease or late-stage cirrhosis of the liver, Giardia antigen presence, Clostridium difficile toxin in stool, tissue transglutaminase antibody, recent change in gastrointestinal medications, use of drugs that affects gastrointestinal motility, and use of any antibiotic in the last two months also will be excluded.","40 Years","70 Years",{"count":162,"type":21},120,[164],"PHASE2","The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.",[167,168,28],"Gulf War Illness","Chronic Fatigue",[170,167,171,172,173,157],"SCFA","GWI","Microbiome","Butyric acid","2025-10-29",{"date":176,"type":33},"2025-10-31",{"date":178,"type":33},"2024-01-15",{"date":180,"type":21},"2027-03-31",{"name":182,"class":114},"VA Office of Research and Development",3,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":192,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":195,"studyType":53,"phases":4,"briefSummary":196,"conditions":197,"keywords":206,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":41},"100484735","early-severe-illness-translational-biology-informatics-in-humans-100484735","NCT05591924","Early Severe Illness TrAnslational BioLogy InformaticS in Humans","Prospective Observational Study of Biology of Critical Illness","ESTABLISH","Inclusion Criteria:\n\n* Age ≥18 years old\n* ≤48h since ICU admission\n* ICU admission within 72h of presentation to the emergency department (ER)\n* Clinical critical illness suspected on the basis of any one of the following:\n\n  1. Altered mental status (GCS\\\u003C15)\n  2. Cardiovascular collapse (presence of any: Heart rate \\>90, systolic blood pressure \\\u003C90, presence of vasopressors, lactate \\>2.0)\n  3. Respiratory collapse (presence of any: respiratory rate \\>20, PaCO₂ \\\u003C32 mm Hg, supplemental oxygen, invasive or non-invasive ventilation)\n  4. Suspected severe infection (presence of any: temperature \\>38°C or \\\u003C36°C, white blood cell (WBC) count \\>12,000\u002Fmm³ or \\\u003C4,000\u002Fmm³, presence of 1 or more antibiotics at the time of ICU admission)\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* \\>72h since ICU admission\n* Admission to ICU in patients \\>72h after the presentation to the ER\n* No evidence of critical illness (ICU admission due to bed-spacing)",true,{"count":194,"type":21},1000,"24 Months","Advanced stages of the response to life-threatening infection, severe trauma, or other physiological insults often lead to exhaustion of the homeostatic mechanisms that sustain normal blood pressure and oxygenation. These syndromic presentations often meet the diagnostic criteria of sepsis and\u002For the acute respiratory distress syndrome (ARDS), the two most common syndromes encountered in the intensive care unit (ICU). Although critical illness syndromes, such as sepsis and ARDS, have separate clinical definitions, they often overlap clinically and share several common injury mechanisms. Moreover, there are no specific therapies for critically ill patients, and as a consequence, approximately 1 in 4 patients admitted to the ICU will not survive.\n\nThe purpose of this observational study is to identify early patient biologic factors that are present at the time of ICU admission that will help diagnose critical illness syndromes earlier, identify who could benefit most from specific therapies, and enable the discovery of new treatments for syndromes such as sepsis and ARDS.",[198,199,200,28,201,202,203,204,205],"Sepsis","ARDS","Critical Illness","Shock, Septic","Ventilator Associated Pneumonia","Immune Suppression","Inflammation","SIRS",[207,198,199,204,208,209,210,211],"Critical Care","Immune responses","Neurocognition","Critical illness","Translational Biology","2025-10-01",{"date":214,"type":33},"2025-10-06",{"date":216,"type":33},"2024-04-26",{"date":218,"type":21},"2034-12-31",{"name":220,"class":73},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":41},"100603740","monitoring-neurocognitive-dysfunction-and-the-impact-of-metabolism-and-physical-capacity-after-paediatric-hsct-100603740","NCT07140445","Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric HSCT","Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric Haematopoietic Stem Cell Transplantation (Abbreviation: MindMe)","MindMe","Inclusion Criteria:\n\n* =\u002F\\> 7 years of age\n* treatment with HSCT in Denmark since 2010\n* treatment with HSCT was before the age of 18 years\n* ability to speak and understand Danish.\n\nExclusion Criteria:\n\n* diagnosed with infantile autism before their HSCT\n* Downs Syndrome","7 Years",{"count":231,"type":21},175,"Today the overall survival of childhood cancers has increased to above 85%. This increase is partially caused by treatment with bone marrow transplantation. A bone marrow transplantation is an efficient treatment against high-risk leukemia, as well as other life-threatening immunological and hematological diseases. However, it is unfortunately also related to the risk of developing a long series of late effects during early adulthood, such as reduced muscle mass, cardiovascular disease and diabetes.\n\nSome survivors of bone marrow transplantation in childhood also seem to experience changes in cognitive functions. These changes may be experienced as difficulties with concentration, forgetfulness, learning difficulties, and challenges in school or the labour market. Currently, the extent of cognitive changes following bone marrow transplantation in childhood is not fully understood, nor how it relates to other late effects, and what can be done to prevent cognitive impairment.\n\nThis research project will examine cognitive function in a group of survivors of bone marrow transplantation in childhood and find out whether there is a correlation between reduced cognitive function and the occurrence of other late effects, including metabolic changes and reduced physical capacity. It will also explore associations between cognitive function at late follow up and blood-based biomarkers of neurological damage and systemic inflammation at the time of transplantation to identify predictors of reduced cognitive function.\n\nThe goal of the study is to evaluate the level of cognitive functioning after bone marrow transplantation in childhood, see how it relates to other late effect and identify risk factors and biomarkers in the blood that can predict which patients are at risk of neurocognitive impairment. The results of this study will hopefully contribute to optimizing the prevention and treatment of cognitive impairments following bone marrow transplantation in childhood, thereby improving the quality of life for survivors of bone marrow transplantation in childhood.",[234,59,28,235,236,62],"Stem Cell Transplant","Paediatric Patients","Metabolic Syndrome","2025-08-27",{"date":239,"type":33},"2025-09-04",{"date":241,"type":21},"2025-09-01",{"date":243,"type":21},"2027-03-01",{"name":72,"class":73},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":253,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":41},"100537223","phase-3-evaluation-of-memantine-in-the-preservation-of-memory-and-neurocognition-following-csi-100537223","NCT06275035","Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI","Memantine to Preserve Memory and Neurocognition Following Craniospinal Irradiation- A Randomised Controlled Trial (MEMENTO)","MEMENTO","Inclusion Criteria:\n\n* Age at irradiation: 5 to 39 years\n* Planned for CSI (with or without boost dose) with or without systemic chemotherapy\n* Informed consent or assent taken\n* Karnofsky Performance Status \u002F Lansky Performance Status ≥ 60\n\nExclusion Criteria:\n\n* Re-irradiation\n* Prior exposure to memantine\n* Inability to undergo Wechsler test","5 Years","39 Years",{"count":256,"type":21},101,[258],"PHASE3","The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.",[28],"2025-04-08",{"date":263,"type":33},"2025-04-09",{"date":265,"type":33},"2024-02-22",{"date":267,"type":21},"2031-01",{"name":269,"class":73},"Tata Memorial Centre",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":278,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":41},"100312194","assessing-neurocognition-after-cerebrovascular-intervention-100312194","NCT03344276","Assessing Neurocognition After Cerebrovascular Intervention","Inclusion Criteria:\n\n* patients \\>18 years of age\n* ultrasound evidence of carotid stenosis; in which the patient has either 50% or greater symptomatic carotid stenosis or 70% or greater asymptomatic carotid stenosis.\n\nExclusion Criteria:\n\n1. patients \\\u003C18 years of age\n2. patients with without compatibility for MRI\n3. patients requiring carotid stenting for reasons not related to long-standing stenosis\n4. patients requiring emergency carotid stenting for acute symptoms such as crescendo transient ischemic attacks, intolerance of physiologic blood pressure.\n5. Patients that do not have appropriate capacity (i.e. understand the risks and benefits associated with this study) or are unable to consent for themselves will not be included in this study.",{"count":277,"type":21},20,[24],"Decreased blood flow to the brain can cause decreased cognitive function. Carotid disease can result in decreased blood flow to the brain. The investigators seek to assess this relationship prospectively through performing a battery of neurocognitive assessments, collection of serum markers of inflammation, and through neuroimaging at two points before intervention (2 months and 1 month before stenting) and at two points after intervention (1 month and 2 months after intervention). The goal is to provide prospective evidence to identify the extent to which carotid stenosis and hypoperfusion of the brain results in diminished neurocognitive performance, and see if serum biomarkers before and after stenting correlate with these findings.",[281,28],"Carotid Artery Diseases",[283,284,285,286],"carotid stenosis","neurocognition","carotid stenting","circle of willis","2025-02-03",{"date":289,"type":33},"2025-02-06",{"date":291,"type":33},"2021-07-15",{"date":293,"type":21},"2025-12",{"name":295,"class":73},"University of California, San Diego",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":327,"locationsCount":183},"100524738","the-dancerex-proof-of-concept-study-for-chronic-neurological-disorders-100524738","NCT06112639","The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders","DANCE REhabilitation Experience (DANCEREX-DTx): Protocol for a Randomized Controlled Trial on Effectiveness of Digital Therapeutics in Chronic Neurological Disabilities","DANCEREX-DTx","Inclusion Criteria:\n\n1. age between 18 and 85 years (adult and older adult);\n2. education equal to or more than five years\n3. agreement to participate with the signature of the informed consent form;\n4. clinical diagnosis of Multiple Sclerosis (MS) according to the 2017 revised criteria of MC Donald - Expanded Disability Status Scale (EDSS) score equal or less than 4.5, R-R disease course, freedom from relapses, and steroid treatment for at least one month, OR clinical diagnosis of pre-Mild Cognitive Impairment - MCI (Subjective Memory Complaints and\u002For Subjective Cognitive Complaints)\u002FMCI at risk of Alzheimer's Disease with the Clinical Dementia Rating (CDR) scale equal or less than 0.5\n5. Normal score to a screening test for cognitive impairment (Montreal Cognitive Assessment test - MoCA test \\> 15.5 Santangelo et al., 2015)\n\nExclusion Criteria:\n\n1. presence of comorbidities that prevent patients from undertaking a safe home program (e.g., balance problems, history of falls in the past 6 months, use of assistive devices for deambulation)\n2. presence of overt hearing\u002Fvisual impairment\n3. for the MCI group, the absence of a caregiver\u002Fstudy partner able to support the participant;\n4. no living in one's own home;\n5. for the MS group, score in cerebellum function at EDSS greater than 3","85 Years",{"count":306,"type":21},192,[24],"The goal of this clinical trial is to test a new digital therapeutic solution which combines a holistic, multidimensional rehabilitation program based on dance and music with an innovative motivational system (DANCEREX-DTx) in Chronic Neurological Disorders (Multiple Sclerosis and pre-Mild Cognitive Impairment - MCI\u002F MCI at risk of Alzheimer's Disease). The main questions it aims to answer are 1\\] efficacy of the digital therapeutic solution in terms of adherence, clinical\u002Ffunctional measures, quality of life and surrogate measures; 2\\] usability and acceptability of the system.\n\nParticipants will be randomized (with an allocation ratio of 2:2:1) into the experimental group (DANCEREX - 24 sessions of multidimensional dance-based program integrated with an innovative motivational system), active comparator group (24 sessions of multidimensional dance-based program) and placebo group (24 sessions of educational program). Researchers will compare the experimental group to the other two groups to see if a digital therapeutic solution integrating a multidimensional dance-based program and motivational system is effective in increasing adherence to rehabilitation treatment.",[310,311,28],"Sclerosis, Multiple","Neurocognitive Impairment, Mild",[313,314,315,316,317,318,319,320],"rehabilitation","multiple sclerosis","dementia","digital therapeutics","neurocognitive dysfunction","MRI","neuroinflammation","telerehabilitation","2025-01-09",{"date":323,"type":33},"2025-01-10",{"date":325,"type":33},"2024-01-31",{"date":176,"type":21},{"name":328,"class":73},"Fondazione Don Carlo Gnocchi Onlus"]